Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

Impact · against what's priced in

The news is non-catalytic for Moderna, Merck, and Nasdaq Inc. as the market has already priced in the stock's massive run-up, the FDA vaccine approvals, the clinical efficacy of the cancer vaccine, and the index inclusion.

MRK+0.00: Already priced in
The price assumes: mRNA cancer vaccine (Intismeran) with Keytruda in melanoma
The mention of the phase 3 trial efficacy for the melanoma treatment confirms a driver the market is already monitoring, providing no new upside.

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

What matters in this story

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

What matters in this story

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

How each ticker is affected

Connected tickers

Track these names every morning.

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

What matters in this story

Next reads from the same story arc

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

What matters in this story

Next reads from the same story arc

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

How each ticker is affected

Connected tickers

Track these names every morning.

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026